CD19 and mixed phenotype acute leukemia: More recent clinical studies have shown that CD19 bispecific T-cell engagers and CAR T cells are promising treatments for MPAL [34,35] and that immunotherapy with blinatumomab can be used as a bridge to HSCT [36,37].